Amylyx Pharmaceuticals, Inc. (AMLX) NASDAQ
13.29
-0.78(-5.54%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.29
-0.78(-5.54%)
Currency In USD
Address
43 Thorndike Street
Cambridge, MA 02141
United States of America (the)
Phone
617 682 0917
Website
Sector
Healthcare
Industry
Biotechnology
Employees
123
First IPO Date
January 07, 2022
| Name | Title | Pay | Year Born |
| Joshua Cohen | Co-Founder, Co-CEO & Director | 1.25M | 1992 |
| Justin Klee | Co-CEO & Director | 1.25M | 1991 |
| Gina Mazzariello | Chief Legal Officer & General Counsel | 715,494 | 1972 |
| James Frates | Chief Financial Officer | 817,183 | 1967 |
| Camille L. Bedrosian | Chief Medical Officer | 1.01M | 1953 |
| Jamie Timmons | Head of Global Medical Strategy & Communications | 0 | N/A |
| Machelle Manuel | Vice President & Head of Global Medical Affairs | 0 | N/A |
| Dan Monahan | Chief Commercial Officer | 0 | N/A |
| Tom Holmes | Chief Technical Operations Officer | 0 | N/A |
| Linda A. Arsenault | Chief Human Resources Officer | 0 | N/A |
| Lindsey Allen | Head of Investor Relations & Communications | 0 | N/A |
| Tammy Sarnelli | Global Head of Regulatory Affairs | 0 | N/A |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.